Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Fischer

Showing results (1331-1340 of 1,361) with videos related to

Pageof 137
Sort By:
Neurology|August 1, 1997
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, D E Goodkin, L D Jacobs, et al.
Annals of Neurology|March 1, 1996
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)L D Jacobs, D L Cookfair, R A Rudick, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degradersYen-Der Li, Michelle W Ma, Muhammad Murtaza Hassan, et al.
Nature|March 28, 2024
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNFSandi Radko-Juettner, Hong Yue, Jacquelyn A Myers, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 1999
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG)D E Goodkin, R L Priore, K E Wende, et al.
Journal of Neuroimmunology|June 23, 1999
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupR A Rudick, D L Cookfair, N A Simonian, et al.
The Journal of Clinical Investigation|June 28, 2022
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cellsRob S Sellar, Adam S Sperling, Mikołaj Słabicki, et al.
Cell|December 4, 2020
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader DevelopmentKatherine A Donovan, Fleur M Ferguson, Jonathan W Bushman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-PredictionKeyan Salari, Debasish Sundi, Jason J Lee, et al.
Nature Biomedical Engineering|September 25, 2023
Allometrically scaling tissue forces drive pathological foreign-body responses to implants via Rac2-activated myeloid cellsJagannath Padmanabhan, Kellen Chen, Dharshan Sivaraj, et al.
Pageof 137

Showing results (1331-1340 of 1,361) with videos related to

Sort By:
Pageof 137
Neurology|August 1, 1997
Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)R A Rudick, D E Goodkin, L D Jacobs, et al.
Annals of Neurology|March 1, 1996
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)L D Jacobs, D L Cookfair, R A Rudick, et al.
Biorxiv : the Preprint Server for Biology|February 24, 2023
Template-assisted covalent modification of DCAF16 underlies activity of BRD4 molecular glue degradersYen-Der Li, Michelle W Ma, Muhammad Murtaza Hassan, et al.
Nature|March 28, 2024
Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNFSandi Radko-Juettner, Hong Yue, Jacquelyn A Myers, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 1999
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG)D E Goodkin, R L Priore, K E Wende, et al.
Journal of Neuroimmunology|June 23, 1999
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research GroupR A Rudick, D L Cookfair, N A Simonian, et al.
The Journal of Clinical Investigation|June 28, 2022
Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cellsRob S Sellar, Adam S Sperling, Mikołaj Słabicki, et al.
Cell|December 4, 2020
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader DevelopmentKatherine A Donovan, Fleur M Ferguson, Jonathan W Bushman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2023
Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-PredictionKeyan Salari, Debasish Sundi, Jason J Lee, et al.
Nature Biomedical Engineering|September 25, 2023
Allometrically scaling tissue forces drive pathological foreign-body responses to implants via Rac2-activated myeloid cellsJagannath Padmanabhan, Kellen Chen, Dharshan Sivaraj, et al.
Pageof 137